acting bronchodilator is recommended in the treatment of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD. Objective: To evaluate the efficacy and tolerability of budesonide/formoterol administered via one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) in patients with COPD. Methods: This was a 6-month, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicentre study (NCT00206154) of 1704 patients aged ≥40 years with moderate to very severe COPD conducted in 194 centres in the US, Czech Republic, the Netherlands, Poland and South Africa. After 2 weeks of treatment based on previous therapy (ICSs and short-acting bronchodilators allowed during the run-in period), patients received one of the following treatments administered twice daily: budesonide/formoterol pMDI 160/4.5 μg × two inhalations (320/9 μg); budesonide/formoterol pMDI 80/4.5 μg × two inhalations (160/9 μg); budesonide pMDI 160 μg × two inhalations (320 μg) plus formoterol DPI 4.5 μg × two inhalations (9 μg); budesonide pMDI 160 μg × two inhalations (320 μg); formoterol DPI 4.5 μg × two inhalations (9 μg); or placebo.
pre-specified primary comparator); budesonide/formoterol 160/9 μg demonstrated significantly greater improvements versus budesonide (p < 0.001) for 1-hour post-dose FEV1 but not versus formoterol for pre-dose FEV1. Dyspnoea (measured using the Breathlessness Diary) and health-related quality-of-life (HR-QOL) scores (based on the St George's Respiratory Questionnaire total score) were significantly improved with both dosage strengths of budesonide/formoterol compared with budesonide, formoterol and placebo (p ≤ 0.044 for all). Although not powered a priori for comparisons, the number of exacerbations per patienttreatment year requiring treatment with oral corticosteroids and/or hospitalization was numerically (20-25%) lower with the budesonide-containing treatments (0.710-0.884) versus formoterol (1.098) and placebo (1.110) . This result was driven by the exacerbations requiring treatment with oral corticosteroids (79-120 events). The number of exacerbations resulting in hospitalization was very low across treatment groups (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) ; the number per patient-treatment year was significantly different for budesonide/formoterol 320/9 μg (0.158) versus other treatment groups (0.081-0.108) except budesonide/formoterol 160/9 μg (0.139), and for budesonide/formoterol 160/9 μg versus formoterol (0.081) [p ≤ 0.05]. All treatments were generally well tolerated. The incidence of individual non-fatal serious adverse events was similar across all treatment groups, except COPD, which was highest in the budesonide/formoterol 320/9 μg group (6.1%) and lowest in the budesonide (3.6%) and formoterol (3.9%) groups, with a range of 4.3-4.6% in the budesonide/formoterol 160/9 μg, budesonide plus formoterol and placebo groups. Budesonide/formoterol had a safety profile comparable with that of the monocomponents and placebo. There was no increase in the incidence of pneumonia in the active treatment groups relative to placebo. Conclusions: Budesonide/formoterol pMDI 320/9 μg demonstrated significantly greater efficacy for pulmonary function on both co-primary endpoints versus the pre-specified comparators (formoterol DPI 9 μg for pre-dose FEV 1 and budesonide pMDI 320 μg for 1-hour post-dose FEV1). Budesonide/formoterol pMDI 160/9 μg demonstrated significantly greater efficacy for 1-hour post-dose FEV1 versus budesonide pMDI 320 μg. Dyspnoea scores and HR-QOL were significantly improved with both budesonide/formoterol pMDI dosage strengths versus both monocomponents and placebo. Both budesonide/formoterol pMDI dosage strengths were well tolerated relative to the monocomponents and placebo.
Background
In patients with COPD, long-acting β2-adrenoceptor agonists (LABAs) have been shown to achieve several of these therapeutic goals, including Chronic obstructive pulmonary disease (COPD) improvement in pulmonary function and COPD is characterized by progressive fixed airflow limitasymptoms, reduction in rescue medication use and tion and an abnormal inflammatory response to noximprovement in health-related quality of life (HRious stimuli. [1] The goals of COPD therapy include QOL). [2] [3] [4] [5] [6] Inhaled corticosteroids (ICSs) reduce the (i) improvements in airflow, exercise tolerance, frequency of exacerbations, [7] [8] [9] but have shown inhealth status and COPD symptoms (e.g. dyspnoea); consistent results in terms of reduction in mortality (ii) prevention of disease progression and exacerba-and modest effects with respect to improvement in tions; and (iii) a reduction in mortality. [1] pulmonary function. [9] [10] [11] [12] [13] [14] [15] [16] The combination of the ICS budesonide and the required to have a history of at least one COPD LABA formoterol administered in a single dry pow-exacerbation treated with a course of oral corticoder inhaler (DPI) [Symbicort ® Turbuhaler ® ; 1 Astra-steroids and/or antibacterials within 1-12 months Zeneca, Lund, Sweden] demonstrated significant before screening (visit 1) and documented use of an improvements in pulmonary function, HR-QOL and inhaled short-acting bronchodilator as rescue medsymptoms, and a significant reduction in exacerba-ication. At screening, spirometry was performed tion rate compared with placebo in patients with before and 15-30 minutes after administration of COPD. [17, 18] Moreover, in comparison with the two inhalations of salbutamol (albuterol) pMDI (tomonocomponents, budesonide/formoterol DPI dem-tal dose 180-200 μg). A prebronchodilator FEV1 of onstrated significant improvements in forced expir-≤50% of predicted normal and a prebronchodilator atory volume in 1 second (FEV1) versus budesonide FEV1/forced vital capacity of <70% were required alone [17, 18] and formoterol alone, [17] and a significant at screening. Additional criteria included a smoking reduction in the rate of severe and overall COPD history of ≥10 pack-years, a score of ≥2 on the exacerbations compared with formoterol alone. [17, 18] Modified Medical Research Council dyspnoea scale at the time of screening, [19] and a breathlessness, The present 6-month study evaluated the efficacy cough and sputum scale (BCSS) score of ≥2 per day and tolerability of budesonide/formoterol adminisfor at least half of the 2-week run-in period. tered via a hydrofluoroalkane (HFA) pressurized metered-dose inhaler (pMDI) [Symbicort ® pMDI;
Patients were excluded if they had any of the AstraZeneca, Charnwood, Loughborough, UK] in following conditions: (i) a history of asthma; (ii) a patients with moderate to very severe COPD. history of allergic rhinitis before 40 years of age; Budesonide/formoterol pMDI was administered in (iii) significant/unstable cardiovascular disorder; two dosage strengths (160/4.5 μg × two inhalations (iv) clinically significant respiratory tract disorder [320/9 μg] and 80/4.5 μg × two inhalations [160/ other than COPD; and (v) homozygous α-1 antitryp-9 μg]), each administered twice daily, and compared sin deficiency or any other clinically significant cowith the monocomponents (administered alone or in morbidities that could preclude participation in the combination via separate inhalers) and placebo. This study or interfere with the study results, as deteris the first time that two doses of budesonide in mined by the investigator. Patients were also excombination with a LABA have been evaluated in cluded if they needed additions or alterations to their the same study in patients with COPD, the results of usual COPD maintenance therapy or an increment which may provide some insight into the efficacy in rescue therapy due to worsening symptoms within and safety implications of differing doses of ICS in 30 days before screening or during the run-in combination with a LABA in clinical practice.
period. Oral or ophthalmic non-cardioselective β-adrenoceptor antagonists, oral corticosteroids, pregPatients and Methods nancy and breast-feeding also were exclusionary.
Study Design and Treatment Patients
The inclusion criteria were designed to enrol This randomized, double-blind, double-dummy, patients with moderate to very severe COPD who placebo-controlled, parallel-group, 6-month study had previous exacerbations and were therefore suit-(NCT00206154) was conducted in 194 centres in able candidates for ICS/LABA combination ther-the US, Czech Republic, the Netherlands, Poland apy. Current or ex-smokers aged ≥40 years with a and South Africa. The study consisted of a screening clinical diagnosis of COPD and symptoms for visit (visit 1), a 2-week run-in period, a randomiza->2 years were eligible for this study. Patients were tion visit (visit 2), four subsequent visits during the 1 The use of trade names is for product identification purposes only and does not imply endorsement. 26-week treatment period and a follow-up telephone Zeneca, Charnwood, Loughborough, UK). Visits call 30 days after the last study visit. During the 3-6 were scheduled at 1, 2, 4 and 6 months after 2-week run-in period, patients continued ICS mono-randomization. Salbutamol was not to be used withtherapy if they had previously been receiving ICS in 6 hours before each clinic visit; inhaled ipratropialone or in combination with a LABA, and patients um bromide was not to be used within 8 hours who had previously been receiving anticholinergic before each clinic visit. Allowed and disallowed therapies were placed on stable doses of ipratropium concomitant medications are described in table I. bromide. A short-acting β2-adrenoceptor agonist The study protocol was approved by a review was allowed for rescue use. At visit 2 (after the run-board and ethics committee at each site, and written in period), any ICS therapy was discontinued and all informed consent was obtained from patients. The patients were then given study rescue medication study was performed in accordance with the ethical (salbutamol pMDI) for as-needed use.
principles based on the Declaration of Helsinki and consistent with the International Conference on HarAt visit 2, eligible patients were randomized in monization/Good Clinical Practice and applicable balanced blocks according to a computer-generated local regulatory requirements. randomization scheme at each site to one of six treatments administered twice daily ( figure 1 ). The present study used formoterol DPI (formoterol
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Turbuhaler ® ; AstraZeneca, Södertälje, Sweden) as the formoterol comparator rather than formoterol
The co-primary efficacy variables were pre-dose pMDI. Results from a previous study in patients FEV1 and 1-hour post-dose FEV1, measured at all with asthma demonstrated equivalent formoterol-clinic visits. Spirometry was performed according to related bronchodilation when formoterol was ad-American Thoracic Society guidelines. [21] Spiromeministered in combination with budesonide via try measurements were performed in the morning at pMDI or alone via DPI. [20] Budesonide was admin-approximately the same time (±1 hour) at each clinic istered via an HFA pMDI (budesonide pMDI; Astra-visit, approximately 12 hours after the previous dose of study medication. Crapo-predicted normals [22] for pleted the validated Breathlessness Diary, a single-FEV1 were used.
item dyspnoea measure derived from the BCSS, [23] on a daily basis. The item was scored on a 5-point Secondary pulmonary function variables includLikert-type scale, ranging from 0 to 4, with higher ed 12-hour spirometry, pre-dose and 1-hour postscores indicating more severe dyspnoea. Based on a dose inspiratory capacity (IC), and morning and previous study, [24] a change of ≥0.2 units in dyspevening peak expiratory flow (PEF). Twelve-hour noea score was identified as clinically relevant (i.e. serial FEV1 was performed in a subset of patients minimal important difference [MID] ) and was spec-(n = 618) pre-dose and at 5, 15, 30, 60, 120, 180, ified a priori. HR-QOL was evaluated at screening, 240, 360, 480, 600 and 720 minutes after adminisrandomization and the end of months 1, 2 and 6 tration of study medication at randomization, and using the St George's Respiratory Questionnaire months 2 and 6. Baseline-adjusted average 12-hour (SGRQ), [25, 26] for which a change of 4 units is con-FEV1 (calculated as the area between the 12-hour sidered clinically meaningful. [27] This threshold for post-dose FEV1 over time curve and the baseline a clinically meaningful change was specified a pripre-dose FEV1 [defined as the last pre-dose FEV1 ori, and patients were categorized as experiencing before the first dose of randomized treatment] dividdecreases or increases of ≥4 units in the SGRQ total ed by the observation time), FEV1 at 12 hours and score. COPD exacerbations, defined as worsening maximum FEV1 were determined. Pre-dose and 1-of COPD symptoms that required treatment with hour post-dose IC were assessed in this subset of oral corticosteroids and/or hospitalization, were repatients. Morning and evening PEF were measured corded by patients in their diary cards and confirmed daily before administration of the morning and by the study coordinators and/or investigators at the evening dose of study medication using a Miniclinic visit. Wright ® peak flow metre (Clement Clark, Inc., Harlow, UK), and the highest of three measurements Secondary symptom variables, including cough was recorded by patients in their diary cards. and sputum scores, sleep score and rescue medSecondary efficacy variables included dyspnoea, ication use, were recorded on a daily basis by pa-HR-QOL and COPD exacerbations. Patients com-tients. Cough and sputum scores were recorded b Allowed if the patient had been using β-adrenoceptor antagonists at a constant dose for 6 months before screening (visit 1) without evidence of bronchospasm.
c Not to be used within 6 hours of each clinic visit.
d Allowed during the run-in period.
ICSs = inhaled corticosteroids; LABA = long-acting β2-adrenoceptor agonist; SABA = short-acting β2-adrenoceptor agonist.
before the evening dose of study medication, and In all patients, blood and urine samples were each were assessed on a scale from 0 to 4, with collected, and comprehensive physical examinahigher scores indicating an increased number of tions were carried out at the time of screening and at symptoms or more severe symptoms. The BCSS is the end of month 6 or the last visit. Blood samples the sum total of the individual dyspnoea, cough and were analysed by a central laboratory (Quest Diagsputum scores, and the total scores range from 0 to nostics Clinical Laboratories, Van Nuys, CA, USA). 12. [23] Sleep score was recorded before the morning Vital signs, including heart rate and blood pressure, dose of study medication and assessed on a scale were measured at all clinic visits. 12-Lead ECGs from 0 to 4, with higher scores indicating more sleep were performed in all patients before and disturbances (based on the number and/or duration 30-60 minutes after inhalation of study drug at of night-time awakenings, including early awaken-randomization and at the end of months 2 and 6. ings, caused by COPD symptoms [e.g. dyspnoea, ECG results were evaluated by a cardiologist in a cough and chest tightness]). Rescue medication use blinded fashion through an independent ECG ser-(inhalations/day) was recorded in the morning and vice provider (eResearch Technology, Inc., Philaevening before administration of study medication. delphia, PA, USA). Clinically important abnormaliThe percentages of awakening-free nights (defined ties and shifts were identified as follows: heart rate as nights for which the patient reported a sleep score >100 beats per minute (bpm) or a change of of 0) and rescue medication-free days (defined as ≥20 bpm from baseline; QT/QTc interval ≥500 msec days for which the patient reported no daytime or or an increase of >60 msec from baseline. Samples night-time rescue medication use) were calculated.
to assess 24-hour urinary cortisol levels were collected in a subset of patients (n = 437) at or before randomization and within 1 week before the 6-Safety Evaluations month visit. The incidence of adverse events (AEs), serious AEs (SAEs) and discontinuations due to AEs Statistical Analyses (DAEs) was assessed. AEs were recorded by the patient on a diary card throughout the study. AEs
The efficacy analysis set (i.e. intention-to-treat also were collected at the beginning of each clinic population) included all randomized patients who visit and during the final follow-up telephone call. received at least one dose of study medication and Symptoms or signs consistent with COPD (e.g. contributed sufficient data for at least one co-primabronchitis, cough, phlegm, increased sputum, dysp-ry or secondary efficacy endpoint during the rannoea, wheeze) were to be reported as AEs only if domized treatment period. The safety analysis poputhey were serious, new to the patient, inconsistent lation included randomized patients who had rewith the patient's pre-existing COPD history within ceived at least one dose of study medication and 1 year of the screening visit or when they resulted in from whom any post-randomization data were availdiscontinuation from the study. Investigators as-able. For the subsets of patients who underwent sessed the causal relationship of AEs to study med-serial spirometry and 24-hour urinary cortisol meaication.
surement, analysis sets were defined as randomized, treated patients who had baseline and on-treatment AEs representing typical class effects associated values for the variable being assessed. with exposure to corticosteroids (e.g. local, systemic) or β2-adrenoceptor agonists (e.g. cardiac ef-A sample size of 190 evaluable patients per treatfects, tremor, anxiety) were described. AEs of oral ment group was estimated to provide ≥90% power candidiasis were based on history/physical examina-to detect a difference of 0.1 L (assuming a standard tion and did not require confirmatory culture. Other deviation of 0.3 L) in the change from baseline in AEs of interest included those related to pneumonia pre-dose FEV1 between treatment groups. The samand other respiratory tract infections.
ple size also provided 80-90% power to detect dif-ferences in dyspnoea scores and SGRQ total score. primary efficacy variables. AE variables were summarized descriptively. All hypothesis testing was conducted using 2-sided tests; p ≤ 0.05 was considered statistically signifResults icant.
The prespecified primary comparators for the coprimary efficacy variables were (i) formoterol DPI Patients for pre-dose FEV1 to demonstrate the contribution Patient disposition is shown in figure 2 . Disconof budesonide to the anti-inflammatory action of tinuation rates were significantly lower in the budesonide/formoterol pMDI; and (ii) budesonide budesonide/formoterol 160/9 μg and 320/9 μg pMDI for 1-hour post-dose FEV1 to demonstrate the groups compared with the placebo, budesonide and contribution of formoterol to the bronchodilator acformoterol groups (p ≤ 0.018). Discontinuation rates tion of budesonide/formoterol pMDI. Analyses of were not significantly different for either of the the primary and key secondary efficacy endpoints monocomponents compared with placebo. The were adjusted for multiplicity using a sequential overall discontinuation rate was higher in the US approach to hypothesis testing at the 5% signifi-(28.6%) than in non-US countries (12.2%). cance level. No formal hypothesis testing of the Demographic and baseline disease characteristics safety data was performed, although treatment difwere generally similar across treatment groups ferences for certain variables are described with (table II) . Approximately half of the patients were confidence intervals and p-values (used as flagging ≥65 years of age and approximately 12% were devices).
≥75 years of age. Most patients had severe (58.2%) Changes from baseline in the co-primary efficacy or very severe (22%) COPD, while 19.3% had modvariables were analysed using an analysis of co-erate and 0.3% had mild COPD, based on postvariance (ANCOVA) model, adjusting for treat-bronchodilator FEV 1 at screening and 2007 Global ment, country and baseline. Changes from baseline Initiative for Chronic Obstructive Lung Disease criin other secondary efficacy variables were analysed teria (0.2% had missing data). [1] The mean preusing methodology similar to that described for the bronchodilator FEV1 at screening was approximateco-primary efficacy variables. A Cochrane-Mantel-ly 34% of predicted normal. Approximately Haenszel test, adjusted for country and prespecified 40-45% of participants were current smokers with a in the statistical analysis plan, was used to separately median smoking history of 40 pack-years. Co-morevaluate the percentages of patients with increases bid conditions affecting the overall population inand decreases that met the MID for SGRQ total cluded hypertension (42%), lipid profile abnormaliscore. The number of exacerbations per patient-ties (24%), cardiac disease (18%), diabetes mellitus treatment year was compared between treatment (10%), osteoporosis (8%) and cataracts (5%). Demgroups using a Poisson regression model, adjusting ographic and baseline disease characteristics were for country, differential time from randomization generally similar across regions, with the exception and over dispersion. In addition, a sensitivity ana-that higher percentages of females and Black palysis, including a region-by-treatment interaction tients were reported in US (41.5% and 8.2%, respecterm, was added to the model for the co-primary tively) versus non-US regions (24.8% and 0.5%, variables to test for treatment differences by region. respectively).
Geometric mean 24-hour urinary cortisol levels
Efficacy Evaluations at the end of treatment were compared between treatment groups using a multiplicative ANCOVA
Co-Primary Efficacy Variables
model. Mean changes from baseline in ECG variables were compared between treatment groups usImprovements in pre-dose FEV1 were signifiing methodology similar to that described for the co-cantly greater in patients who were treated with The efficacy analysis set included 1697 patients. Seven patients were excluded because of an early study site closure; data from these patients were included in the safety analysis set. AE = adverse event; BUD = budesonide; DPI = dry powder inhaler; FM = formoterol; med = medication; PL = placebo; pMDI = pressurized metered-dose inhaler.
budesonide/formoterol 320/9 μg compared with for-apparent at the first assessment after randomization (month 1) following treatment with both budesomoterol (primary comparison), budesonide and planide/formoterol dosage strengths and were generally cebo (p ≤ 0.026; table III). Budesonide/formoterol maintained over the 6-month treatment period with 160/9 μg demonstrated significantly greater imbudesonide/formoterol 320/9 μg (figure 3a). provements in pre-dose FEV1 compared with budesonide and placebo (p ≤ 0.002), but not comImprovements in 1-hour post-dose FEV 1 were pared with formoterol (the pre-specified primary significantly greater in the budesonide/formotercomparator). Treatment with formoterol also result-ol 320/9 μg group compared with the budesonide ed in significantly greater improvements in pre-dose (p < 0.001; primary comparison), formoterol FEV1 compared with placebo (p = 0.037). Patients (p = 0.039) and placebo (p < 0.001) groups (table treated with budesonide did not experience signif-III). Treatment with budesonide/formoterol 160/ icant improvements in pre-dose FEV1 compared 9 μg resulted in significantly greater improvements in 1-hour post-dose FEV1 compared with budesowith placebo. Improvements in pre-dose FEV1 were a Baseline is defined as the last pre-dose FEV1 value before the first dose of randomized treatment. BUD = budesonide; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FM = formoterol; ICS = inhaled corticosteroid; LABA = long-acting β2-adrenoceptor agonist; PL = placebo; pMDI = pressurized metered-dose inhaler; SABA = short-acting β2-adrenoceptor agonist. III) . Improvements were apparent on the day of randomization and were maintained over the 6-month treatment period after treatment with both budesonide/formoterol dosage strengths and formoterol ( figure 3b) .
The results of the region-by-treatment interaction sensitivity analyses for the co-primary efficacy variables were not significant for either variable (p ≥ 0.148).
Secondary Pulmonary Function Variables
Both budesonide/formoterol dosage strengths resulted in significantly greater mean improvements in baseline-adjusted average 12-hour FEV1 compared with budesonide and placebo at randomization and end of treatment (p ≤ 0.012, all comparisons); budesonide/formoterol 320/9 μg demonstrated significantly greater improvements compared with formoterol at end of treatment (p = 0.030). Patients receiving budesonide/formoterol combination therapy or formoterol alone experienced a mean improvement in FEV1 of approximately 15-18% at 5 minutes after dose administration at the randomization visit (figure 4a) and end of treatment (figure 4b); an improvement in FEV1 of ≥15% is generally considered clinically significant. At the 12-hour timepoint, significant improvements in FEV1 were observed at randomization for both budesonide/formoterol dosage strengths compared with budesonide and placebo (p ≤ 0.006) and for formoterol compared with placebo (p < 0.001); this effect was maintained at end of treatment for budesonide/formoterol 320/9 μg (p ≤ 0.019 vs budesonide, formoterol and placebo). Significantly greater adjusted mean improvements from baseline in maximum FEV1 during 12-hour serial spirometry were observed on the day of randomization for budesonide/ formoterol 320/9 μg (0.32 L) and 160/9 μg (0. μg.
b Baseline defined as the last pre-dose FEV1 value before the first dose of randomized treatment. c Baseline defined as the mean of values obtained during the last 10 days of the run-in period. BUD = budesonide; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FM = formoterol; LS = least squares; PEF = peak expiratory flow; PL = placebo; pMDI = pressurized metered-dose inhaler; * p ≤ 0.001, † p < 0.05, ‡ p < 0.01.
ferent between the treatment groups. Improvements in morning and evening PEF were significantly greater for both budesonide/formoterol dosage strengths compared with budesonide, formoterol and placebo (p ≤ 0.016) and for formoterol compared with placebo (p ≤ 0.004; table III).
Secondary Efficacy Variables
Patients treated with both budesonide/formoterol dosage strengths experienced significantly greater improvements in dyspnoea scores compared with budesonide, formoterol and placebo (p ≤ 0.044; table IV). Improvements in dyspnoea were clinically meaningful (i.e. reduction of ≥0. The total number of COPD exacerbations requiring Improvements in the SGRQ total scores were hospitalization was very low in all treatment groups significantly greater (p ≤ 0.035) in both budesonide/ (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] ; the number of events per patientformoterol groups compared with the budesonide, treatment year was significantly different for formoterol and placebo groups (table V). These budesonide/formoterol 320/9 μg (0.158) compared improvements were clinically meaningful (i.e. re-with other treatment groups (0.081-0.108) except duction from baseline of ≥4 points) for both budeso-budesonide/formoterol 160/9 μg (0.139), and for nide/formoterol dosage strengths compared with budesonide/formoterol 160/9 μg compared with fortheir baseline values at all timepoints assessed (fig-moterol (0.081) (p ≤ 0.05). ure 5). However, differences between the active treatment and placebo groups in SGRQ total score Safety Evaluations did not reach the MID at the end of the treatment period (based on comparison of least squares mean
The mean duration of exposure to randomized changes from baseline). A significantly (p ≤ 0.018) treatment was lowest in the placebo group (150.0 greater percentage of patients in the budesonide/ days) compared with the budesonide/formoterol formoterol 320/9 μg (45.5%) and budesonide/for-320/9 μg (166.5 days), budesonide/formoterol 160/ moterol 160/9 μg (45.4%) groups demonstrated a 9 μg (168.3 days) and budesonide plus formoterol clinically meaningful decrease (i.e. improvement) (164.6 days) groups. Both budesonide/formoterol from baseline to end of treatment in SGRQ total dosage strengths were well tolerated relative to score compared with patients in the placebo group budesonide, formoterol and placebo. The percentage (35.0%). Conversely, the percentage of patients with of patients with at least one AE was generally simiincreases (i.e. worsening) in SGRQ total score from lar across treatment groups: budesonide/formoterol baseline to end of treatment was significantly 320/9 μg (57.4%), budesonide/formoterol 160/9 μg (p ≤ 0.047) lower in the budesonide/formoterol 320/ (52.3%), budesonide plus formoterol (49.5%), 9 μg (22.5%) and budesonide/formoterol 160/9 μg budesonide (57.5%), formoterol (56.7%) and place-(23.3%) groups compared with the placebo (31.1%) bo (50.7%). Overall, the majority of AEs were of group. mild (51.4%) or moderate (36.1%) intensity, with a similar distribution of intensities observed across While this study was not powered to show a treatment groups. difference in exacerbations, the number of COPD exacerbations (requiring oral corticosteroids and/or
The most commonly reported AEs (by ≥3% of hospitalization) per patient-treatment year was nu-randomized patients) were COPD, nasopharyngitis, 
Percentage of awakening-free nights
Mean baseline (SD) DAEs occurred in 133 patients: 19 (6.9%) in the budesonide/formoterol 320/9 μg group, 19 (6.8%) in the budesonide/formoterol 160/9 μg group, 13 (4.5%) in the budesonide plus formoterol group, 25 (9.1%) in the budesonide group, 32 (11.3%) in the formoterol group and 25 (8.3%) in the placebo group. The most common DAE was COPD, which occurred at a higher incidence in the budesonide (5.8%), formoterol (7.4%) and placebo (5%) groups compared with the budesonide and formoterol combination therapy groups (2.9-3.8%).
Considering the severity of the COPD population in this study, there were only 11 deaths reported during randomized treatment, all of which were classified as SAEs that were not considered to be related to the study medication. Three deaths occurred in the budesonide/formoterol 320/9 μg group (nerve root lesion and metastatic lung cancer; cardiac failure; hip fracture and subsequent cardiopulmonary failure), four in the budesonide/formoterol 160/9 μg group (COPD; cardiac arrest; congestive heart failure and COPD; COPD), two in the budesonide group (COPD; cerebrovascular accident), one in the formoterol group (myocardial infarction) and one in the placebo group (subarachnoid haemorrhage).
The incidence of individual non-fatal SAEs was similar across treatment groups, except for COPD, which was highest in the budesonide/formoterol 320/9 μg group, lowest in the budesonide and formoterol groups and similar in the budesonide/formoterol 160/9 μg, budesonide plus formoterol and placebo groups (table VII) . Overall, the most common individual non-fatal SAEs (occurring in at least three randomized patients) were COPD (4.5%), pneumonia (0.6%), atrial fibrillation (0.5%), prostate cancer (0.2%), congestive heart failure (0.2%), 
No. of patients respiratory failure (0.2%) and acute bronchitis was low, with a similar incidence observed across (0.2%). The overall incidence of non-fatal SAEs, all treatment groups (2.8-3.5%) . unadjusted for treatment exposure time, was 11.2% Despite the known association of ICSs with in the budesonide/formoterol 320/9 μg group, pneumonia, [13] there was no difference between 10.7% in the budesonide/formoterol 160/9 μg treatment groups in the incidence of pneumoniagroup, 9.1% in the budesonide plus formoterol related AEs (table VIII) . For lung infections other group, 9.5% in the budesonide group, 8.1% in the than pneumonia, the incidence was higher in all formoterol group and 8.3% in the placebo group.
active treatment groups, except budesonide/formoterol 160/9 μg, compared with the placebo group; The incidence of AEs typically associated with these differences were driven largely by bronchitis local effects of corticosteroids (e.g. candidiasis, (table VIII) . Two patients had DAEs of pneumonia voice effects) was highest in the budesonide/formo-(one in the budesonide group and one in the placebo terol 320/9 μg (6.9%) and budesonide (5.5%) group) and 13 patients had pneumonia-related SAEs groups, and lowest in the budesonide/formoterol that occurred during or after the randomized treat-160/9 μg (3.2%), budesonide plus formoterol ment period with no preponderance for any specific (3.1%), formoterol (3.2%) and placebo (2.3%) treatment group noted (budesonide/formoterol 320/ groups. The incidence of AEs potentially associated 9 μg [n = 1]; budesonide/formoterol 160/9 μg with systemic effects of corticosteroids (e.g. bone [n = 3] ; budesonide plus formoterol [n = 2]; budesoeffects, diabetes control, skin effects, weight gain, nide [n = 3] ; formoterol [n = 3] ; placebo [n = 1]). ocular effects, taste effects, adrenal suppression) The overall incidence of AEs potentially or typiCompared with patients in non-US regions, patients enrolled in centres in the US had a higher cally associated with β2-adrenoceptor agonists efoverall incidence of AEs (63.6% vs 46.8%), a higher fects (i.e. headache, sleep effects, muscle cramps, overall incidence of AEs per patient-treatment year anxiety, serum potassium decrease, serum glucose (3.9 vs 2.0) and a higher incidence of drug-related increase, palpitation, tremor, tachycardia, agitation) AEs (13.2% vs 3.3%). The incidence of individual was low (5.9%), ranging from 4.9% (budesonide AEs generally was similar across the regions. plus formoterol) to 7.5% (budesonide/formoterol Clinically significant changes in vital signs, 160/9 μg) across treatment groups. The incidence of physical examinations or ECG measures were rare, cardiac-related AEs was slightly higher in the with no clinically important differences observed budesonide plus formoterol (6.6%) and budesonide between the budesonide/formoterol groups and the (6.5%) groups compared with the budesonide/for-budesonide, formoterol and placebo groups. There moterol 320/9 μg (5.1%), budesonide/formoterol were no clinically important differences between the 160/9 μg (5.3%), formoterol (4.6%) and placebo treatment groups in mean changes from baseline, (4%) groups. The most common cardiovascular-shifts from baseline or the incidence of clinically important abnormalities for ECG variables. related AEs were hypertension (1.4%), atrial fibrillation (0.6%), angina pectoris (0.4%), congestive
The observed changes from baseline and differheart failure (0.4%), coronary artery disease (0.4%), ences between the treatment groups in geometric blood pressure increase (0.4%) and myocardial is-mean 24-hour urinary cortisol (nmol/24 hours) were chaemia (0.3%).
not considered clinically important. Geometric mean 24-hour urinary cortisol values in the formo-the budesonide/formoterol 320/9 μg group, three in terol group increased by 30.6% from baseline at the budesonide plus formoterol group, two in the month 6 and by 29.2% from baseline at end of budesonide group and one in the placebo group. treatment, while values in the budesonide-containing treatment groups decreased by 23.6-35.8% Discussion from baseline to month 6 and by 24.2-35.8% from baseline at end of treatment. Treatment with placebo
The results of the present study demonstrated the resulted in slight decreases in geometric mean 24-efficacy of budesonide/formoterol 320/9 μg for both hour urinary cortisol at month 6 (6.1%) and end of co-primary endpoints (pre-dose FEV1 and 1-hour treatment (7.1%). Adjusted geometric mean 24-hour post-dose FEV1) compared with formoterol 9 μg, urinary cortisol values at months 6 and end of treat-budesonide 320 μg and placebo in patients with ment were significantly lower for both budesonide/ moderate to very severe COPD, indicating the indiformoterol dosage strengths compared with formo-vidual contributions of budesonide and formoterol. terol (p ≤ 0.001) and for budesonide/formoterol 320/ Budesonide/formoterol 160/9 μg also demonstrated 9 μg and budesonide compared with placebo significantly better results on both co-primary end-(p ≤ 0.023), and significantly higher for formoterol points compared with budesonide and placebo, but compared with placebo (p ≤ 0.038). Ten patients had not compared with formoterol; the latter finding a shift in 24-hour urinary cortisol from normal at may be related to the substantial efficacy observed baseline to low at end of treatment: four patients in with formoterol. The population of the present study was selected observed differences may be related to the differing to include patients with moderate to very severe methodologies used during the run-in periods of COPD who had experienced exacerbations and were these studies. Previous studies that demonstrated therefore likely to be treated with ICS/LABA com-significant improvements from baseline with ICS bination therapy. Consequently, all patients were compared with placebo evaluated pulmonary funccurrent (40-45% of patients) or previous smokers tion using baseline values after a run-in period with a median smoking history of 40 pack-years. during which patients received rescue medication This study allowed enrolment of patients with sig-alone. [18, 28, 29] Treatment with rescue medication nificant co-morbidities, such as hypertension, lipid alone during the run-in period may have affected profile abnormalities, cardiac disease, diabetes, os-baseline values and margins for improvement teoporosis and cataracts, therefore resembling real during the randomized treatment period in those clinical practice conditions. By allowing patients to studies. In contrast, patients in the present study receive therapy based on previous treatment during were generally maintained on their previous therthe run-in period, the study was designed to avoid apy, including ICS, because of the widespread availsubstantial deterioration in COPD symptoms during ability of long-term maintenance therapies at the the run-in period before patients began randomized time the present study was conducted. Therefore, in treatment.
the present study, patients received therapy during the run-in period based on their previous treatment In the present study, treatment with budesonide to avoid substantial deterioration in COPD sympalone did not improve pre-dose FEV1 or 1-hour toms, which may have accounted for the lack of post-dose FEV1 compared with placebo. These redemonstrable effect of budesonide alone on FEV1. sults are similar to those reported by Calverley et However, the significantly greater improvements in al., [17] who demonstrated no significant improvepre-dose FEV1 and 1-hour post-dose FEV1 observed ment in post-dose FEV1 following treatment with with budesonide/formoterol 320/9 μg compared budesonide compared with placebo in patients with with formoterol in the present study suggest that severe COPD. In contrast, other studies have dembudesonide in combination with formoterol contribonstrated significant improvements in pre-and postutes to improvement in pulmonary function. dose FEV1 in patients with moderate to very severe COPD receiving budesonide [18] or fluticasone proThe present study is the first to evaluate two pionate [28, 29] alone compared with placebo. These dosage strengths of ICS/LABA combination therapy ions (Newtown, PA, USA) for writing assistance funded by on clinical judgment, without radiological confirmaAstraZeneca LP, the study sponsor, which designed the study tion in all cases. In the present study, all active and participated in the management, analysis and interpretatreatments, except budesonide/formoterol 160/9 μg, tion of the data, and in the review and approval of the article. exhibited a higher incidence of bronchitis compared Dr Tashkin has served as a consultant for AstraZeneca, with placebo. However, the full clinical characteri-Boehringer-Ingelheim, Dey Laboratories and ScheringPlough; received honoraria from AstraZeneca, Boehringerzation of these bronchitic episodes is not clear from Ingelheim and Dey Laboratories; and received or will receive the information collected in this study. In addition, grants from Almirall, AstraZeneca, Boehringer-Ingelheim, there was a slightly higher incidence of non-fatal Dey Laboratories, Novartis, Pfizer, Sepracor and Forest LabSAEs in patients receiving budesonide/formoterol oratories. Dr Rennard has served as a consultant or on the compared with budesonide, formoterol and placebo, advisory board for Adams, Almirall, Altana, AstraZeneca,
